ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma
Gene expression profiling revealed ADAM9 to be distinctly overexpressed in pancreatic ductal adenocarcinoma (PDAC). We examined the relevance of ADAM9 expression in PDAC diagnosis and prognosis. A total of 59 infiltrating PDACs, 32 specimens from patients with chronic pancreatitis, 11 endocrine tumo...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2004-03, Vol.90 (5), p.1053-1058 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1058 |
|---|---|
| container_issue | 5 |
| container_start_page | 1053 |
| container_title | British journal of cancer |
| container_volume | 90 |
| creator | Grützmann, R Lüttges, J Sipos, B Ammerpohl, O Dobrowolski, F Alldinger, I Kersting, S Ockert, D Koch, R Kalthoff, H Schackert, H K Saeger, H D Klöppel, G Pilarsky, C |
| description | Gene expression profiling revealed ADAM9 to be distinctly overexpressed in pancreatic ductal adenocarcinoma (PDAC). We examined the relevance of ADAM9 expression in PDAC diagnosis and prognosis. A total of 59 infiltrating PDACs, 32 specimens from patients with chronic pancreatitis, 11 endocrine tumours and 24 acinar cell carcinomas were immunohistochemically analysed for ADAM9 expression. Staining for ADAM9 was detected in 58 out of 59 (98.3%) PDACs and in two out of 24 (8.3%) acinar cell carcinomas, but not in endocrine tumours. In the non-neoplastic pancreas, whether normal or chronically inflamed, ADAM9 was expressed in centroacinar and intralobular duct cells, but not in interlobular duct cells and their hyperplastic lesions. Pancreatic ductal adenocarcinomas showing cytoplasmic ADAM9 expression correlated with poor tumour differentiation and also with shorter overall survival than in cases showing only an apical membranous staining pattern (
P
=0.001). Multivariate analysis identified cytoplasmic ADAM9 expression as an independent marker of shortened survival in a set of 42 curatively (R0) resected PDAC (
P |
| doi_str_mv | 10.1038/sj.bjc.6601645 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2409625</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>984038721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c571t-dcc2446cbbd9b75350de638177ceac99f6519588540af0c2c8afe0a6f8f92eba3</originalsourceid><addsrcrecordid>eNqFkkuPFCEUhStG47SjW3caYqJxUz1AFa_NJJ3xmYxxo2tyi6J66FRDCZTO_Htpu51WE3UF5Hz3ACenqh4TvCS4kWdps-w2Zsk5Jrxld6oFYQ2tiaTibrXAGIsaK4pPqgcpbcpRYSnuVyekVUpQLBbV9erV6oNC9nqKNiUXPHIeTeBNtJCdQaZsbUQuIUgpGAfZ9uiby1coz9swR5RvJovA9z8QNMWw9iHtJgcwOcSdXT-bDCOC3vpgIBrnwxYeVvcGGJN9dFhPq89vXn-6eFdffnz7_mJ1WRsmSK57Y2jbctN1veoEaxjuLW8kEcJYMEoNnBHFpGQthgEbaiQMFgMf5KCo7aA5rc73vtPcbW1vrM8RRj1Ft4V4owM4_bvi3ZVeh6-atlhxyorBi4NBDF9mm7LeumTsOIK3YU5aEK6kpLiAL_8JEimYZE0j8H89ieCSt1wV8Nkf4KaE7ktgmlKluKJNU6DlHjIxpBTtcPs7gvWuJTptdGmJPrSkDDz9NZMjfqhFAZ4fAEgGxiGWFrh05BhTglNeuLM9l4rk1zYen_fXq5_sJzzkOdpby5_6dwJQ4a4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229969233</pqid></control><display><type>article</type><title>ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma</title><source>MEDLINE</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Grützmann, R ; Lüttges, J ; Sipos, B ; Ammerpohl, O ; Dobrowolski, F ; Alldinger, I ; Kersting, S ; Ockert, D ; Koch, R ; Kalthoff, H ; Schackert, H K ; Saeger, H D ; Klöppel, G ; Pilarsky, C</creator><creatorcontrib>Grützmann, R ; Lüttges, J ; Sipos, B ; Ammerpohl, O ; Dobrowolski, F ; Alldinger, I ; Kersting, S ; Ockert, D ; Koch, R ; Kalthoff, H ; Schackert, H K ; Saeger, H D ; Klöppel, G ; Pilarsky, C</creatorcontrib><description>Gene expression profiling revealed ADAM9 to be distinctly overexpressed in pancreatic ductal adenocarcinoma (PDAC). We examined the relevance of ADAM9 expression in PDAC diagnosis and prognosis. A total of 59 infiltrating PDACs, 32 specimens from patients with chronic pancreatitis, 11 endocrine tumours and 24 acinar cell carcinomas were immunohistochemically analysed for ADAM9 expression. Staining for ADAM9 was detected in 58 out of 59 (98.3%) PDACs and in two out of 24 (8.3%) acinar cell carcinomas, but not in endocrine tumours. In the non-neoplastic pancreas, whether normal or chronically inflamed, ADAM9 was expressed in centroacinar and intralobular duct cells, but not in interlobular duct cells and their hyperplastic lesions. Pancreatic ductal adenocarcinomas showing cytoplasmic ADAM9 expression correlated with poor tumour differentiation and also with shorter overall survival than in cases showing only an apical membranous staining pattern (
P
=0.001). Multivariate analysis identified cytoplasmic ADAM9 expression as an independent marker of shortened survival in a set of 42 curatively (R0) resected PDAC (
P
<0.05, hazard ratio 2.85, 95% confidence interval: 1.21–6.71). The results show that ADAM9 expression distinguishes PDACs from other solid pancreatic tumours. In addition, cytoplasmic ADAM9 overexpression is associated with poor differentiation and shortened survival. Therefore, ADAM9 overexpression might contribute to the aggressiveness of PDACs.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6601645</identifier><identifier>PMID: 14997207</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>ADAM Proteins ; Adenocarcinoma - metabolism ; Adenocarcinoma - pathology ; Adult ; Aged ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Acinar Cell - metabolism ; Carcinoma, Acinar Cell - pathology ; Carcinoma, Pancreatic Ductal - metabolism ; Carcinoma, Pancreatic Ductal - pathology ; Cell Differentiation ; Chronic Disease ; Cytoplasm ; Disintegrins - metabolism ; Drug Resistance ; Epidemiology ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunoenzyme Techniques ; Islets of Langerhans - metabolism ; Islets of Langerhans - pathology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Membrane Proteins - metabolism ; Metalloendopeptidases - metabolism ; Middle Aged ; Molecular and Cellular Pathology ; Molecular Medicine ; Oncology ; Pancreatic cancer ; Pancreatic Ducts - metabolism ; Pancreatic Ducts - pathology ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Pancreatitis - metabolism ; Pancreatitis - pathology ; Prognosis ; Survival Rate ; Tumors</subject><ispartof>British journal of cancer, 2004-03, Vol.90 (5), p.1053-1058</ispartof><rights>The Author(s) 2004</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Mar 8, 2004</rights><rights>Copyright © 2004 Cancer Research UK 2004 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c571t-dcc2446cbbd9b75350de638177ceac99f6519588540af0c2c8afe0a6f8f92eba3</citedby><cites>FETCH-LOGICAL-c571t-dcc2446cbbd9b75350de638177ceac99f6519588540af0c2c8afe0a6f8f92eba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409625/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409625/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2725,27923,27924,41487,42556,51318,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15597626$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14997207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grützmann, R</creatorcontrib><creatorcontrib>Lüttges, J</creatorcontrib><creatorcontrib>Sipos, B</creatorcontrib><creatorcontrib>Ammerpohl, O</creatorcontrib><creatorcontrib>Dobrowolski, F</creatorcontrib><creatorcontrib>Alldinger, I</creatorcontrib><creatorcontrib>Kersting, S</creatorcontrib><creatorcontrib>Ockert, D</creatorcontrib><creatorcontrib>Koch, R</creatorcontrib><creatorcontrib>Kalthoff, H</creatorcontrib><creatorcontrib>Schackert, H K</creatorcontrib><creatorcontrib>Saeger, H D</creatorcontrib><creatorcontrib>Klöppel, G</creatorcontrib><creatorcontrib>Pilarsky, C</creatorcontrib><title>ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Gene expression profiling revealed ADAM9 to be distinctly overexpressed in pancreatic ductal adenocarcinoma (PDAC). We examined the relevance of ADAM9 expression in PDAC diagnosis and prognosis. A total of 59 infiltrating PDACs, 32 specimens from patients with chronic pancreatitis, 11 endocrine tumours and 24 acinar cell carcinomas were immunohistochemically analysed for ADAM9 expression. Staining for ADAM9 was detected in 58 out of 59 (98.3%) PDACs and in two out of 24 (8.3%) acinar cell carcinomas, but not in endocrine tumours. In the non-neoplastic pancreas, whether normal or chronically inflamed, ADAM9 was expressed in centroacinar and intralobular duct cells, but not in interlobular duct cells and their hyperplastic lesions. Pancreatic ductal adenocarcinomas showing cytoplasmic ADAM9 expression correlated with poor tumour differentiation and also with shorter overall survival than in cases showing only an apical membranous staining pattern (
P
=0.001). Multivariate analysis identified cytoplasmic ADAM9 expression as an independent marker of shortened survival in a set of 42 curatively (R0) resected PDAC (
P
<0.05, hazard ratio 2.85, 95% confidence interval: 1.21–6.71). The results show that ADAM9 expression distinguishes PDACs from other solid pancreatic tumours. In addition, cytoplasmic ADAM9 overexpression is associated with poor differentiation and shortened survival. Therefore, ADAM9 overexpression might contribute to the aggressiveness of PDACs.</description><subject>ADAM Proteins</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Acinar Cell - metabolism</subject><subject>Carcinoma, Acinar Cell - pathology</subject><subject>Carcinoma, Pancreatic Ductal - metabolism</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Cell Differentiation</subject><subject>Chronic Disease</subject><subject>Cytoplasm</subject><subject>Disintegrins - metabolism</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Islets of Langerhans - metabolism</subject><subject>Islets of Langerhans - pathology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Membrane Proteins - metabolism</subject><subject>Metalloendopeptidases - metabolism</subject><subject>Middle Aged</subject><subject>Molecular and Cellular Pathology</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Ducts - metabolism</subject><subject>Pancreatic Ducts - pathology</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatitis - metabolism</subject><subject>Pancreatitis - pathology</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkkuPFCEUhStG47SjW3caYqJxUz1AFa_NJJ3xmYxxo2tyi6J66FRDCZTO_Htpu51WE3UF5Hz3ACenqh4TvCS4kWdps-w2Zsk5Jrxld6oFYQ2tiaTibrXAGIsaK4pPqgcpbcpRYSnuVyekVUpQLBbV9erV6oNC9nqKNiUXPHIeTeBNtJCdQaZsbUQuIUgpGAfZ9uiby1coz9swR5RvJovA9z8QNMWw9iHtJgcwOcSdXT-bDCOC3vpgIBrnwxYeVvcGGJN9dFhPq89vXn-6eFdffnz7_mJ1WRsmSK57Y2jbctN1veoEaxjuLW8kEcJYMEoNnBHFpGQthgEbaiQMFgMf5KCo7aA5rc73vtPcbW1vrM8RRj1Ft4V4owM4_bvi3ZVeh6-atlhxyorBi4NBDF9mm7LeumTsOIK3YU5aEK6kpLiAL_8JEimYZE0j8H89ieCSt1wV8Nkf4KaE7ktgmlKluKJNU6DlHjIxpBTtcPs7gvWuJTptdGmJPrSkDDz9NZMjfqhFAZ4fAEgGxiGWFrh05BhTglNeuLM9l4rk1zYen_fXq5_sJzzkOdpby5_6dwJQ4a4</recordid><startdate>20040308</startdate><enddate>20040308</enddate><creator>Grützmann, R</creator><creator>Lüttges, J</creator><creator>Sipos, B</creator><creator>Ammerpohl, O</creator><creator>Dobrowolski, F</creator><creator>Alldinger, I</creator><creator>Kersting, S</creator><creator>Ockert, D</creator><creator>Koch, R</creator><creator>Kalthoff, H</creator><creator>Schackert, H K</creator><creator>Saeger, H D</creator><creator>Klöppel, G</creator><creator>Pilarsky, C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20040308</creationdate><title>ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma</title><author>Grützmann, R ; Lüttges, J ; Sipos, B ; Ammerpohl, O ; Dobrowolski, F ; Alldinger, I ; Kersting, S ; Ockert, D ; Koch, R ; Kalthoff, H ; Schackert, H K ; Saeger, H D ; Klöppel, G ; Pilarsky, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c571t-dcc2446cbbd9b75350de638177ceac99f6519588540af0c2c8afe0a6f8f92eba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>ADAM Proteins</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Acinar Cell - metabolism</topic><topic>Carcinoma, Acinar Cell - pathology</topic><topic>Carcinoma, Pancreatic Ductal - metabolism</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Cell Differentiation</topic><topic>Chronic Disease</topic><topic>Cytoplasm</topic><topic>Disintegrins - metabolism</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Islets of Langerhans - metabolism</topic><topic>Islets of Langerhans - pathology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Membrane Proteins - metabolism</topic><topic>Metalloendopeptidases - metabolism</topic><topic>Middle Aged</topic><topic>Molecular and Cellular Pathology</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Ducts - metabolism</topic><topic>Pancreatic Ducts - pathology</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatitis - metabolism</topic><topic>Pancreatitis - pathology</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grützmann, R</creatorcontrib><creatorcontrib>Lüttges, J</creatorcontrib><creatorcontrib>Sipos, B</creatorcontrib><creatorcontrib>Ammerpohl, O</creatorcontrib><creatorcontrib>Dobrowolski, F</creatorcontrib><creatorcontrib>Alldinger, I</creatorcontrib><creatorcontrib>Kersting, S</creatorcontrib><creatorcontrib>Ockert, D</creatorcontrib><creatorcontrib>Koch, R</creatorcontrib><creatorcontrib>Kalthoff, H</creatorcontrib><creatorcontrib>Schackert, H K</creatorcontrib><creatorcontrib>Saeger, H D</creatorcontrib><creatorcontrib>Klöppel, G</creatorcontrib><creatorcontrib>Pilarsky, C</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grützmann, R</au><au>Lüttges, J</au><au>Sipos, B</au><au>Ammerpohl, O</au><au>Dobrowolski, F</au><au>Alldinger, I</au><au>Kersting, S</au><au>Ockert, D</au><au>Koch, R</au><au>Kalthoff, H</au><au>Schackert, H K</au><au>Saeger, H D</au><au>Klöppel, G</au><au>Pilarsky, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2004-03-08</date><risdate>2004</risdate><volume>90</volume><issue>5</issue><spage>1053</spage><epage>1058</epage><pages>1053-1058</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Gene expression profiling revealed ADAM9 to be distinctly overexpressed in pancreatic ductal adenocarcinoma (PDAC). We examined the relevance of ADAM9 expression in PDAC diagnosis and prognosis. A total of 59 infiltrating PDACs, 32 specimens from patients with chronic pancreatitis, 11 endocrine tumours and 24 acinar cell carcinomas were immunohistochemically analysed for ADAM9 expression. Staining for ADAM9 was detected in 58 out of 59 (98.3%) PDACs and in two out of 24 (8.3%) acinar cell carcinomas, but not in endocrine tumours. In the non-neoplastic pancreas, whether normal or chronically inflamed, ADAM9 was expressed in centroacinar and intralobular duct cells, but not in interlobular duct cells and their hyperplastic lesions. Pancreatic ductal adenocarcinomas showing cytoplasmic ADAM9 expression correlated with poor tumour differentiation and also with shorter overall survival than in cases showing only an apical membranous staining pattern (
P
=0.001). Multivariate analysis identified cytoplasmic ADAM9 expression as an independent marker of shortened survival in a set of 42 curatively (R0) resected PDAC (
P
<0.05, hazard ratio 2.85, 95% confidence interval: 1.21–6.71). The results show that ADAM9 expression distinguishes PDACs from other solid pancreatic tumours. In addition, cytoplasmic ADAM9 overexpression is associated with poor differentiation and shortened survival. Therefore, ADAM9 overexpression might contribute to the aggressiveness of PDACs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>14997207</pmid><doi>10.1038/sj.bjc.6601645</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2004-03, Vol.90 (5), p.1053-1058 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2409625 |
| source | MEDLINE; Nature Journals Online; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | ADAM Proteins Adenocarcinoma - metabolism Adenocarcinoma - pathology Adult Aged Biological and medical sciences Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Acinar Cell - metabolism Carcinoma, Acinar Cell - pathology Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Cell Differentiation Chronic Disease Cytoplasm Disintegrins - metabolism Drug Resistance Epidemiology Gastroenterology. Liver. Pancreas. Abdomen Humans Immunoenzyme Techniques Islets of Langerhans - metabolism Islets of Langerhans - pathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Membrane Proteins - metabolism Metalloendopeptidases - metabolism Middle Aged Molecular and Cellular Pathology Molecular Medicine Oncology Pancreatic cancer Pancreatic Ducts - metabolism Pancreatic Ducts - pathology Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pancreatitis - metabolism Pancreatitis - pathology Prognosis Survival Rate Tumors |
| title | ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A13%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ADAM9%20expression%20in%20pancreatic%20cancer%20is%20associated%20with%20tumour%20type%20and%20is%20a%20prognostic%20factor%20in%20ductal%20adenocarcinoma&rft.jtitle=British%20journal%20of%20cancer&rft.au=Gr%C3%BCtzmann,%20R&rft.date=2004-03-08&rft.volume=90&rft.issue=5&rft.spage=1053&rft.epage=1058&rft.pages=1053-1058&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6601645&rft_dat=%3Cproquest_pubme%3E984038721%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229969233&rft_id=info:pmid/14997207&rfr_iscdi=true |